• X-press Tag Peptide for RHEB Assays

  2026-09-16

  Build cleaner recombinant RHEB workflows with an N-terminal leader peptide that supports ProBond capture, Anti-Xpress antibody detection, and optional enterokinase removal. This guide connects practical purification decisions with the UBE2F-SAG-RHEB findings while clearly separating assay utility from biological proof.

• Cefazedone: Reading MIC Evidence for Better Assays

  2026-09-16

  Cefazedone (Refosporen) is examined through a practical evidence framework that connects comparative MIC testing with assay design, spectrum interpretation, and cautious PK/PD translation. Learn how to use historical β-lactam data without overstating clinical or experimental conclusions.

• Tyrothricin: From Membrane Action to Translation

  2026-09-15

  A mechanism-first guide to using Tyrothricin as a peptide antibiotic mixture, connecting membrane-disruption assays with lessons from adaptive resistance research in melanoma.

• PA-824: From TB Mechanism to Regimen Strategy

  2026-09-15

  PA-824 is more than a potent tuberculosis research compound: its dual effects on mycolate biosynthesis and respiratory metabolism make it a strategic probe for designing regimens that address replicating, non-replicating, and drug-resistant Mycobacterium tuberculosis.

• Temafloxacin: Applied Assay Workflows

  2026-09-14

  Temafloxacin supports quantitative susceptibility testing, comparative fluoroquinolone studies, and targeted intracellular antibacterial workflows. This guide translates reference-study findings into practical assay setup, optimization, troubleshooting, and cross-application decisions.

• Paroxetine Effects on Thiothixene Pharmacokinetics

  2026-09-14

  The 1997 reference study tested whether short-term paroxetine pretreatment altered thiothixene disposition in healthy volunteers, using a randomized two-period pharmacokinetic design. No measured thiothixene pharmacokinetic parameter changed significantly, supporting the view that CYP2D6 is not a dominant clearance pathway while preserving important uncertainty about longer inhibition and broader patient populations.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-09-13

  GI 254023X is a selective ADAM10 inhibitor for connecting sheddase activity with endothelial barrier protection and Notch1 pathway readouts. This guide translates product specifications and reference-study principles into practical workflows for HPAEC, Jurkat, and preclinical vascular assays, with troubleshooting guidance for selectivity, solubility, and assay interpretation.

• Rifampin: From Mechanism to Assay Architecture

  2026-09-12

  Rifampin is a rifamycin antibiotic that enables precise bacterial transcription perturbation. This guide advances beyond routine workflows by showing how to connect molecular inhibition, exposure controls, resistance interpretation, and orthogonal assay design.

• Tyrothricin: A Membrane Assay Framework

  2026-09-11

  Tyrothricin is a peptide antibiotic mixture suited to mechanistic studies of microbial membrane injury. This article presents an assay-centered framework that connects membrane readouts with the experimental logic of recent trigeminal ganglion research without overstating translational relevance.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-11

  The reference study identifies CD44 as a functional metabolic dependency of IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, glycolytic suppression, NADPH production, and sustained R-2HG synthesis. Its isogenic genetic models and combination experiments support CD44 blockade as a mechanistic strategy to investigate resistance to mutant-IDH inhibition in acute myeloid leukemia.

• Amikacin and the New Logic of Resistance Research

  2026-09-10

  Amikacin (BAY416651) can do more than serve as an antimicrobial readout. Paired with carbapenemase localization, conjugation, mobile-element analysis, and strain typing, it helps translational researchers connect ribosomal action with the movement and expression of resistance in high-priority Enterobacterales.

• Cefoperazone Sodium Salt: Research Evidence

  2026-09-10

  Cefoperazone sodium salt is a broad-spectrum semisynthetic cephalosporin used in antibacterial, β-lactamase-resistance, and biliary tract infection research. Product data describe strong gram-negative coverage, high biliary distribution after intravenous administration, and practical DMSO and water solubility parameters.

• Haloprogin Research Workflows

  2026-09-09

  Haloprogin supports controlled studies of dermatophytes, Candida, and selected Gram-positive bacteria through matched MIC, MFC, formulation, and topical infection workflows. Its historical comparison with tolnaftate makes it especially useful for testing broader antimicrobial coverage and translating in vitro findings into animal-model designs.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-09-09

  Lutomski and colleagues developed a native top-down mass spectrometry workflow that releases membrane proteins and signaling complexes directly from retinal disc membranes, preserving links between proteoforms, lipid modifications, and ligand interactions. The study shows how this approach can resolve PDE6 off-target binding and reveal why protein lipidation may influence drug recognition in a native signaling environment.

• Vancomycin Workflows for Resistance Research

  2026-09-08

  Build more reproducible antibacterial assays with Vancomycin, from DMSO stock preparation to broth microdilution and MRSA-focused resistance studies. This workflow also shows how the reference study’s comparative design can improve controls, isolate handling, and interpretation without confusing temafloxacin findings with Vancomycin performance.

7995 records 1/533 page Next 12345 下5页 Last page